. . . . . . . . . . . "approved"@en . "investigational"@en . "Mitiglinide is a drug for the treatment of type 2 diabetes .Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells."@en . . . . . . . . . "KAD-1229"@en . . . . . . . . . . . "Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules. "@en . " "@en . "Mitiglinide"@en . . . "145375-43-5"@en . . . . . . "For the treatment of type 2 diabetes."@en . . . "Mitiglinide calcium hydrate"@en . .